Last mentioned: Feb 19, 2026
Health experts and economists are advocating for a subscription-based 'Netflix' model for antibiotics to combat the rise of superbugs. This proposed shift aims to decouple pharmaceutical profits from sales volume, incentivizing R&D in a sector currently plagued by market failure.
Experts are calling for a radical shift in antibiotic procurement, moving toward a subscription-based 'Netflix model' to incentivize the development of new drugs against resistant superbugs. This approach aims to decouple pharmaceutical revenue from sales volume, ensuring a steady supply of critical treatments as antimicrobial resistance escalates globally.
Health experts are advocating for a 'Netflix-style' subscription model to incentivize the development of new antibiotics as global superbug deaths rise. This proposed shift would decouple pharmaceutical profits from sales volume, ensuring a stable revenue stream for life-saving drugs that must be used sparingly.